Biogen (BASE:BIIBD) - Stock Price, News & Analysis

BIIBD Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

About the company

BIIBD fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 45.2% below our estimate of its fair value

Earnings are forecast to grow 17.83% per year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Profit margins (12.1%) are lower than last year (31%)

Biogen Inc. Competitors

Celltrion

KOSE:A068270

₩39.2t

BioNTech

NasdaqGS:BNTX

US$21.4b

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$15.3b

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share Price	US$16.25
52 Week High	US$30.50
52 Week Low	US$16.25
Beta	-0.0089
1 Month Change	-17.09%
3 Month Change	-26.14%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-40.26%

Recent updates

Shareholder Returns

	BIIBD	AR Biotechs	AR Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how BIIBD performed against the AR Biotechs industry.

Return vs Market: Insufficient data to determine how BIIBD performed against the AR Market.

Price Volatility

Is BIIBD's price volatile compared to industry and market?
BIIBD volatility
BIIBD Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in AR Market	0%
10% least volatile stocks in AR Market	0%

Stable Share Price: BIIBD's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine BIIBD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1978	7,570	Chris Viehbacher	www.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIBD fundamental statistics
Market cap	US$31.38b
Earnings (TTM)	US$1.17b
Revenue (TTM)	US$9.66b

26.8x

P/E Ratio

3.2x

P/S Ratio

Is BIIBD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIIBD income statement (TTM)
Revenue	US$9.66b
Cost of Revenue	US$4.70b
Gross Profit	US$4.96b
Other Expenses	US$3.79b
Earnings	US$1.17b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	8.01
Gross Margin	51.34%
Net Profit Margin	12.07%
Debt/Equity Ratio	43.0%

How did BIIBD perform over the long term?

See historical performance and comparison

BIIBD Stock Overview

Rewards

Risk Analysis

Biogen Inc. Competitors

KOSE:A068270

₩39.2t

NasdaqGS:BNTX

US$21.4b

NasdaqGS:HZNP

US$26.6b

NasdaqGS:BMRN

US$15.3b

Price History & Performance

Recent News & Updates

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Recent updates

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Biogen Inc. Provides Earnings Guidance for the Year 2023

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Authorization Application for Lecanemab

Biogen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Biogen Names Priya Singhal as Executive Vice President, Head of Development

U.S. Food and Drug Administration Accepts Biogen Inc.'s Biologics License Application for BIIB800

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Biogen Inc. Announces European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of Als

Biogen Inc. Announces Executive Changes

Biogen Inc. Revises Revenue Guidance for the Full Year 2022

Biogen Inc. Announces FDA's 3-Month Extension of Review Period for the New Drug Application for Tofersen

Biogen Inc. to Report Q3, 2022 Results on Oct 25, 2022

Biogen Inc. and Denali Therapeutics Announce Initiation of the Phase 3 Lighthouse Study in Parkinson's Disease Associated with Lrrk2 Pathogenic Mutations

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Boston Properties, Inc. (NYSE:BXP) acquired 125 Broadway, A six story 271,000 Square Foot Laboratory/Life Sciences Property from Biogen Inc. (NasdaqGS:BIIB) for $592 million.

Biogen Inc. Announces That the New England Journal of Medicine Has Published A Second Manuscript Detailing Positive Results from the Company’s Two-Part Phase 2 Lilac Study, Which Evaluated Litifilimab, an Investigational Drug, in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Biogen Inc. Announces FDA Accepts its New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

Biogen Inc. Updates Earnings Guidance for Full Year 2022

Biogen Inc. to Report Q2, 2022 Results on Jul 20, 2022

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization Accepts A New Role Outside of Biogen, Inc, Effective June 30, 2022

Biogen Inc. Presents New Data from Clinical Studies Aimed at Assessing Remaining Unmet Needs for People Living with Spinal Muscular Atrophy and Evaluating the Potential Impact of SPINRAZA

Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate At the Annual European Congress of Rheumatology (EULAR 2022)

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Shareholder Returns